Head to head
Eloralintide against Petrelintide
The two selective amylin agonists furthest along outside the Novo programme, both aiming at weight loss with less gastrointestinal burden than GLP-1 drugs. Same class, same argument, no head to head.
Column A
EloralintideEloralintide (LY3841136)
Lilly's selective amylin agonist that reached about 20% weight loss in Phase 2 with milder gut side effects than GLP-1 drugs, now in Phase 3 alone and as an add-on to tirzepatide.
Column B
PetrelintidePetrelintide (long-acting amylin analogue)
A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results.
Side by side, on the facts we can check
| Attribute | Eloralintide | Petrelintide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; Phase 3 (ENLIGHTEN program) | Investigational (Phase 3 planned to start in the second half of 2026) |
| Half-life | Weekly dosing (long-acting) | Supports weekly dosing |
| Molecular weight | 4,526 Da | 4,192 Da |
| Mechanism | Activates amylin receptors (calcitonin receptor plus RAMP complexes), slowing gastric emptying and reducing appetite through a pathway that is independent of GLP-1. | Agonizes amylin receptors to promote satiety and slow gastric emptying, used as a single-agent weight-loss approach. |
| Human studies cited | 3 | 2 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Eloralintide and Petrelintide?
Eloralintide: Lilly's selective amylin agonist that reached about 20% weight loss in Phase 2 with milder gut side effects than GLP-1 drugs, now in Phase 3 alone and as an add-on to tirzepatide. Petrelintide: A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results.
Which has stronger research evidence, Eloralintide or Petrelintide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Eloralintide profile were human work, against 2 of 3 for Petrelintide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Eloralintide and Petrelintide FDA-approved?
Eloralintide: Investigational; Phase 3 (ENLIGHTEN program). Petrelintide: Investigational (Phase 3 planned to start in the second half of 2026).
Related posts
Blog articles that cover Eloralintide or Petrelintide, newest first.
- Metabolic / Sep 8, 2026 / 9 minCagrilintide: The Amylin Half of CagriSema, and Why People Search 'Cagrilintide with Retatrutide'
- Metabolic / Sep 8, 2026 / 9 minRetatrutide vs Tirzepatide vs Semaglutide vs the Pill: The 2026 GLP-1 Field Guide
- Research / Sep 8, 2026 / 11 minNew Peptides and Longevity Compounds in 2026: What Is Actually New, What Is Newly Legal, and What Is Just New to Vendors
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.